India 
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Earnings Call audio Unaudited
Unaudited
Q4
(Jan – Mar)
Audited
Unaudited
Unaudited
Unaudited
Q4
(Jan – Mar)
Audited
Q3
(Oct – Dec)
Unaudited
Q2
(July – Sep)
Unaudited
Unaudited
Q4
(Jan – Mar)
Audited
Q3
(Oct – Dec)
Unaudited
Q2
(July – Sep)
Unaudited
Q1
(April – June)
Unaudited
Q4
(Jan – Mar)
Audited
-
FINANCIAL YEAR 2025
Tax Transparency Report (3 MB)Independent Assurance Statement (IR) (1 MB)Independent Assurance Statement (BRSR) (798 KB)Human Rights Assessment Declaration (166 KB)Disclosure pursuant to SEBI (Share Based Employee
Benefits and Sweat Equity Regulations), 2021(515 KB)Impact Assessment Report of CSR (2 MB)Lupin ESG Supplementary Report FY 2024-25 (2 MB)Lupin LCA Report (147 KB) -
FINANCIAL YEAR 2024
Tax Transparency Report (2 MB)DNV Assurance Certificate (IR) (226 KB)DNV Assurance Certificate (BRSR) (331 KB)Human Rights Assessment Declaration (125 KB)Disclosure pursuant to SEBI (Share Based Employee
Benefits and Sweat Equity Regulations), 2021(908 KB)Compliance Certificate under SEBI (Share Based
Employee Benefits and Sweat Equity Regulations), 2021(134 KB) -
FINANCIAL YEAR 2023
S&P Global CSA Score 2023: 69/100 (52.2 KB )Tax Transparency Report (2 MB)Transition Risks Report (4 MB)TCFD Report (7.1 MB)Assurance Certificate (236 KB) -
-
2025- 2024
- 2023
- 2022
- 2021
2024
2023
2022
2021- US FDA inspection at Goa
- Newspaper Ad – Q2 FY26 financial results
- Related Party Transactions – September 30, 2025
- Newspaper ad – Re-lodgement of transfer requests for physical shares
- Allotment of shares under ESOP
- Earnings call Q2 FY26
- ESOP
- U.S. FDA Pre-Approval Inspection of Somerset Facility in the U.S.
- Plans to build a new state-of-the-art manufacturing facility at coral springs.
- USFDA inspection of Pithampur facility
- Retirement – member of senior management
- Acquisition of VISUfarma
- Stocks options
- USFDA inspection of Biotech faciliy
- ESG ratings
- Schedule of analyst – investor meet
- USFDA inspection at Aurangabad
- Re-lodgement of transfer request of physical shares
- Crisil ESG Ratings & Analytics Ltd
- Analyst/Investors Meet
- Reappointment of
Mr. Mark D. McDade - ESOP allocation –
Aug 21, 2025 - SE intimation of ESOP
- SE intimation of term
- Outcome of AGM and e-voting Results
- BSE/NES Letter Schedule of Analyst Investors Meet
- 1stAugust 2025
- USFDA inspection Pithampur Unit 3
- USFDA inspection Pithampur Unit 2
- Allotment of shares under ESOP
- 43rd AGM intimation
- ESG rating from NSE Sustainability Ratings & Analytics Limited
- Newspaper Ad – relodgement of physical share transfer requests
- NSE BSE Letter Closure of Trading Window
- BSE Letter Zentiva Signed
- SE intimation Updates API R&D-Final
- NSE intimation Execution of BTAOTC Business
- Employees Stock Option Plan
- BSE / NSE Letter Schedule of Analyst Investors Meet
- Change in Directors
- SE Intimation Updates API R&D and OTC Business
- BSE / NSE Letter Acquisition of Renascience Pharma Limited
- BSE / NSE Letter Retirement of SMP
- SE Intimation Outcome of Board Meeting
- Voting Results March 2025
- BSE/NSE Letter Incoporation LHCL
- SE Intimation Newspaper Advt
- BSE/NSE Letter Schedule of Analyst Investors Meet
- BSE/NSE Letter Action taken by Authority
- BSE/NSE Letter Verification of News Article
- Stock Exchange Intimation
- BSE/NSE Letter Sunsure Acquisition
- BSE / NSE Letter Schedule of Analyst Investors Meet.
- BSE / NSE Letter Schedule of Analyst Investors Meet.
- Appointment of Claus Jepsen as President, Global Specialty
- BSE / NSE Letter U.S. FDA Inspection of the Company’s Biotech Facility in Pune
- Bse / Nse Letter U.S. FDA Inspection of the Company’s Manufacturing Facility at Pithampur Unit-1.
- Bse / Nse Letter Schedule of Analyst Investors Meet.
- Appointment of CEO – Lupin Manufacturing Solutions.
- Business Transfer Agreement with Lupin Life Sciences Limited.
- BSE / NSE Acquisition Brands Sanofi.
- BSE / NSE Reg30 Settlement Agreement Glumetza.
- BSE / NSE Letter Somerset Regulation.
- Disclosure pursuant to Regulation 42 and 44 of SEBI.
- Disclosure pursuant to Regulation 30 of SEBI.
- BSE / NSE Re-launch of Mirabegron Extended-Release (ER) Tablets 25 mg in the United States.
- Bse / Nse Change In Directors.
- Order from Office of the Deputy Commissioner of State Tax, CT and GST Circle, Cuttack – I West Circle, Orissa.
- BSE/NSE Disclosure Letter-4.
- BSE/NSE Disclosure Letter-3.
- BSE/NSE Disclosure Letter-2.
- State tax intimation.
- Appointment of Chief Quality Officer.
- Income Tax intimation.
- Generic business carve out – Lupin Life Sciences Limited (LLSL).
- Letter rec’d regarding input tax credit Patna depot.
- Appointment of Chief Technical Officer.
- USFDA inspection at Aurangabad.
- Business Transfer Agreement with Lupin Manufacturing Solutions Limited (LMSL) – transaction complete.
- Acquisition of a portfolio of accretive established products in Europe and Canada.
- Business Transfer Agreement with LMSL
- Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).
- Disclosure pursuant to Regulation 30 of SEBI (Lupin Manufacturing Solutions Ltd)
- BSE-NSE-Letter-Disclosure pursuant to regulation 30 of SEBI.
- USFDA warning – Tarapur – Sept 29
- Brand acquisition from Boehringer Ingelheim International GmbH –
Aug 24 - USFDA EIR – Somerset – Jul 7
- USFDA audit – Tarapur – Apr 5
- Acquisition of portfolio of brands from Anglo-French Drugs & Industries Limited – Apr 1
- Acquisition of portfolio of brands of Anglo-French – Jan 18
-
Shareholder Services
-
Investor Relations
Subscribe for Investor updates